Market Cap 35.18M
Revenue (ttm) 4.01M
Net Income (ttm) -26.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -672.57%
Debt to Equity Ratio 0.00
Volume 34,200
Avg Vol 58,212
Day's Range N/A - N/A
Shares Out 9.26M
Stochastic %K 29%
Beta -0.63
Analysts Strong Sell
Price Target $22.14

Company Profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 744 4400
Address:
20 Park Plaza, Suite 424, Boston, United States
Ghostofgreg1
Ghostofgreg1 May. 12 at 8:09 PM
$CRVO Its an absolute insult to shareholders to send out proxies to pay these guys even more and ”re elect” board mmembers Announce SOMETHING of substance!! Till then GFY
1 · Reply
BPler
BPler May. 11 at 5:51 PM
$MS Morgan Stanley has significantly increased its position in CervoMed Inc $CRVO , according to a Schedule 13G/A filing dated May 11, 2026, reporting an 8.0% ownership stake. The filing indicates beneficial ownership of 739,736 shares of common stock, with holdings primarily managed through Morgan Stanley Capital Services LLC. https://ir.cervomed.com/node/12016/html
0 · Reply
BPler
BPler May. 11 at 1:51 PM
Biotech in transformation $MRNA with over 21b market cap and biotech going into phase 3 $CRVO with 0.036 b market cap. Last one comes with more risk, but also greater upside potential. In either case the right timing makes difference between +10% or multiple + x00%. I hope in CervoMeds case they will just announce whatever financing they are planing soon, until then big Investors will always wait in hope to get the shares later cheaper.
1 · Reply
5layer
5layer May. 8 at 7:40 PM
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR May. 6 at 6:43 PM
$CRVO no position here but maybe ted turner's estate should fund this https://www-aljazeera-com.cdn.ampproject.org/c/s/www.aljazeera.com/amp/news/2026/5/6/cnn-founder-ted-turner-dead-at-87
0 · Reply
GibsonFlyingV
GibsonFlyingV May. 5 at 5:48 PM
$CRVO just jumped in
0 · Reply
Ghostofgreg1
Ghostofgreg1 May. 5 at 5:40 PM
$CRVO First Quarterly of the year is due this week. Not like they have anything but it sure would be nice for them to announce some funding from a big pharma type to keep the dream alive. That sure would be nice.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 5 at 3:41 AM
$CRVO RSI: 22.58, MACD: -0.1249 Vol: 0.13, MA20: 3.88, MA50: 4.06 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BPler
BPler Apr. 29 at 7:17 PM
$CRVO Study record for PPA (Primary Progressive Aphasia) was updated recently https://clinicaltrials.gov/study/NCT07033481?intr=Neflamapimod&viewType=Card&rank=5&tab=history&a=4#version-content-panel
1 · Reply
ProfitMaker4
ProfitMaker4 Apr. 29 at 2:54 PM
$CRVO Accumulating at these levels, sub $4 is a steal. LT
0 · Reply
Latest News on CRVO
CervoMed presents neflamapimod MRI data

2026-04-22T14:32:59.000Z - 20 days ago

CervoMed presents neflamapimod MRI data


CervoMed Transcript: The 38th Annual Roth Conference

Mar 23, 2026, 3:00 PM EDT - 7 weeks ago

CervoMed Transcript: The 38th Annual Roth Conference


CervoMed’s neflamapimod shows efficacy in dementia with DLB

2026-03-19T11:56:17.000Z - 7 weeks ago

CervoMed’s neflamapimod shows efficacy in dementia with DLB


CervoMed price target lowered to $11 from $19 at Roth Capital

2026-03-17T23:00:26.000Z - 2 months ago

CervoMed price target lowered to $11 from $19 at Roth Capital


CervoMed price target raised to $21 from $15 at Chardan

2026-03-17T22:25:46.000Z - 2 months ago

CervoMed price target raised to $21 from $15 at Chardan


CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024

2026-03-17T11:46:53.000Z - 2 months ago

CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024


CervoMed completes Phase 1 volunteer study for neflamapimod

2026-03-04T12:41:24.000Z - 2 months ago

CervoMed completes Phase 1 volunteer study for neflamapimod


CervoMed initiated with an Overweight at Cantor Fitzgerald

2025-12-18T11:40:57.000Z - 5 months ago

CervoMed initiated with an Overweight at Cantor Fitzgerald


CervoMed’s neflamapimod shows efficacy in slowing dementia

2025-12-04T22:05:45.000Z - 5 months ago

CervoMed’s neflamapimod shows efficacy in slowing dementia


CervoMed price target lowered to $19 from $20 at Roth Capital

2025-11-10T19:35:22.000Z - 6 months ago

CervoMed price target lowered to $19 from $20 at Roth Capital


CervoMed reports Q3 EPS (84c), consensus (56c)

2025-11-10T12:11:54.000Z - 6 months ago

CervoMed reports Q3 EPS (84c), consensus (56c)


CervoMed upgraded to Buy from Neutral at H.C. Wainwright

2025-11-05T11:15:32.000Z - 6 months ago

CervoMed upgraded to Buy from Neutral at H.C. Wainwright


CervoMed appoints Quigley to board of directors

2025-10-28T12:31:51.000Z - 7 months ago

CervoMed appoints Quigley to board of directors


CervoMed Transcript: Emerging Growth Conference

Oct 22, 2025, 11:25 AM EDT - 7 months ago

CervoMed Transcript: Emerging Growth Conference


CervoMed to Present at the Emerging Growth Conference

Oct 20, 2025, 8:00 AM EDT - 7 months ago

CervoMed to Present at the Emerging Growth Conference


CervoMed price target raised to $20 from $16 at Roth Capital

2025-10-17T10:31:09.000Z - 7 months ago

CervoMed price target raised to $20 from $16 at Roth Capital


CervoMed announce new data from Phase 2b trial of RewinD-LB

2025-10-08T11:05:49.000Z - 7 months ago

CervoMed announce new data from Phase 2b trial of RewinD-LB


CervoMed to Participate in Upcoming Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 9 months ago

CervoMed to Participate in Upcoming Investor Conferences


CervoMed Transcript: Status Update

Jul 28, 2025, 8:00 AM EDT - 10 months ago

CervoMed Transcript: Status Update


CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals


CervoMed Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 3:00 PM EST - 1 year ago

CervoMed Transcript: Stifel 2024 Healthcare Conference


CervoMed Transcript: Status Update

Jul 23, 2024, 10:00 AM EDT - 1 year ago

CervoMed Transcript: Status Update


CervoMed to Participate in the Emerging Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference


CervoMed to Appoint William Elder as Chief Financial Officer

May 20, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Appoint William Elder as Chief Financial Officer


CervoMed to Participate in the BIO CEO and Investor Conference

Feb 21, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the BIO CEO and Investor Conference


CervoMed to Participate in the Emerging Growth Conference 67

Feb 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 67


CervoMed to Participate in the Emerging Growth Conference 66

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66


Ghostofgreg1
Ghostofgreg1 May. 12 at 8:09 PM
$CRVO Its an absolute insult to shareholders to send out proxies to pay these guys even more and ”re elect” board mmembers Announce SOMETHING of substance!! Till then GFY
1 · Reply
BPler
BPler May. 11 at 5:51 PM
$MS Morgan Stanley has significantly increased its position in CervoMed Inc $CRVO , according to a Schedule 13G/A filing dated May 11, 2026, reporting an 8.0% ownership stake. The filing indicates beneficial ownership of 739,736 shares of common stock, with holdings primarily managed through Morgan Stanley Capital Services LLC. https://ir.cervomed.com/node/12016/html
0 · Reply
BPler
BPler May. 11 at 1:51 PM
Biotech in transformation $MRNA with over 21b market cap and biotech going into phase 3 $CRVO with 0.036 b market cap. Last one comes with more risk, but also greater upside potential. In either case the right timing makes difference between +10% or multiple + x00%. I hope in CervoMeds case they will just announce whatever financing they are planing soon, until then big Investors will always wait in hope to get the shares later cheaper.
1 · Reply
5layer
5layer May. 8 at 7:40 PM
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR May. 6 at 6:43 PM
$CRVO no position here but maybe ted turner's estate should fund this https://www-aljazeera-com.cdn.ampproject.org/c/s/www.aljazeera.com/amp/news/2026/5/6/cnn-founder-ted-turner-dead-at-87
0 · Reply
GibsonFlyingV
GibsonFlyingV May. 5 at 5:48 PM
$CRVO just jumped in
0 · Reply
Ghostofgreg1
Ghostofgreg1 May. 5 at 5:40 PM
$CRVO First Quarterly of the year is due this week. Not like they have anything but it sure would be nice for them to announce some funding from a big pharma type to keep the dream alive. That sure would be nice.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 5 at 3:41 AM
$CRVO RSI: 22.58, MACD: -0.1249 Vol: 0.13, MA20: 3.88, MA50: 4.06 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BPler
BPler Apr. 29 at 7:17 PM
$CRVO Study record for PPA (Primary Progressive Aphasia) was updated recently https://clinicaltrials.gov/study/NCT07033481?intr=Neflamapimod&viewType=Card&rank=5&tab=history&a=4#version-content-panel
1 · Reply
ProfitMaker4
ProfitMaker4 Apr. 29 at 2:54 PM
$CRVO Accumulating at these levels, sub $4 is a steal. LT
0 · Reply
Ghostofgreg1
Ghostofgreg1 Apr. 29 at 1:57 PM
$CRVO Cant believe still slowly drifting away Crooks
1 · Reply
Silver_Bishop
Silver_Bishop Apr. 26 at 7:53 PM
$CRVO Thanks for keeping the optimism going on this board. As soon as we know how they will finance p3, blue skies. Data is fantasic, trial is as optimised as can be. Just tell us where the money is coming from!
1 · Reply
BPler
BPler Apr. 26 at 6:41 PM
$CRVO Canaccord Genuity also confirmed BUY with 27 USD leading concluding to: Currently, the analyst consensus on CervoMed is a Strong Buy with an average price target of $20.80, representing a 425.3% upside. In a report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $11.00 price target. (Source: https://www.tipranks.com/stocks/crvo?ref=MCO_STOCK&utm_source=theglobeandmail.com&utm_medium=referral)
0 · Reply
Doki0926
Doki0926 Apr. 24 at 2:26 PM
$CRVO this stock is a tragedy
0 · Reply
BPler
BPler Apr. 24 at 1:39 PM
$CRVO also this week 31 USD PT confirmed, failing to gap up for months on good news. Hopefully there will be a breakout soon https://www.gurufocus.com/news/8810244/crvo-maintained-by-d-boral-capital-price-target-steady-at-31?mobile=true
0 · Reply
BPler
BPler Apr. 24 at 1:36 PM
$CRVO Just for the sake of it, PT still 25 with BUY reiterated https://www.gurufocus.com/news/8812254/crvo-reiterated-by-hc-wainwright-co-price-target-maintained-at-25?mobile=true
0 · Reply
focafoca99
focafoca99 Apr. 23 at 5:45 AM
$CRVO furnished an 8-K attaching Exhibit 99.1 and related corporate materials. https://www.rapidticker.com/news/crvo-sec-filing-a6d39f
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Apr. 23 at 4:41 AM
$CRVO good drugs die without funding, I've seen it too many times. Unfortunately Alan & boger should take the shitty pipe deal and accept 2x, 3x warrant coverage. Dilute themselves down, part of something is better than all of nothing. Probably could of taken it at $10 or $8.X but got greedy and now under $4. I love a come back story, I hope they do it. I have no shares anymore, I usually don't hold for funding but I thought boger would make it happen. Sad days.
1 · Reply
focafoca99
focafoca99 Apr. 22 at 6:40 PM
$CRVO presented AAN 2026 data showing neflamapimod increased basal forebrain volume and functional connectivity in dementia with Lewy bodies. https://www.rapidticker.com/news/crvo-cervomed-announces-new-data-at-c31100
0 · Reply
Ghostofgreg1
Ghostofgreg1 Apr. 22 at 6:40 PM
$CRVO WHAT will it take??? This is BS
1 · Reply
LowCountryHooker
LowCountryHooker Apr. 22 at 12:09 PM
$CRVO Today at the #AANAM, we’re sharing the first-ever MRI analyses from our Phase 2b study of neflamapimod, which suggest that neflamapimod may increase the size and enhance the function of the basal forebrain in patients with dementia with Lewy bodies (DLB). Basal forebrain atrophy is the primary driver of disease expression and progression in DLB. We plan to incorporate this technology into our Phase 3 trial DLB which, subject to financing, we plan to start later this year. You can read more here: https://lnkd.in/eXvF8gPf #DLB #neflamapimod
1 · Reply
BPler
BPler Apr. 22 at 11:45 AM
$CRVO For those who don't follow the science in detail: The data presented on April 22, 2026, at the AAN Annual Meeting is being hailed as a major breakthrough because it represents the first time a therapeutic candidate has demonstrated the potential to reverse brain atrophy in patients with Dementia with Lewy Bodies (DLB).
2 · Reply